問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 110Taipei CitySin Yi

Recruiting Trial

211Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

424Cases

2014-11-03 - 2016-11-01

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF AC 201 IN SUBJECTS WITH GOUT

  • Condition/Disease

    Osteoarthritis

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

黃春明
China Medical University Hospital

Division of Rheumatology

2016-05-04 - 2020-10-31

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL OF AC-201 CONTROLLED RELEASE TABLETS IN SUBJECTS WITH HEMOPHILIC ARTHROPATHY

  • Condition/Disease

    HEMOPHILIC ARTHROPATHY

  • Test Drug

    AC-201CR

Participate Sites
6Sites

Terminated5Sites

張家堯
Taipei Medical University Hospital

Division of Hematology & Oncology

邱世欣
Kaohsiung Municipal Gangshan Hospital

未分科

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-09-25 - 2022-11-17

Phase I/II

A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects with Mild to Moderate Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis (AD)

  • Test Drug

    AR100DP1

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新
Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄
Taipei Medical University Hospital

Division of Hematology & Oncology

2018-03-01 - 2020-02-29

Phase II

A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects with Hair Loss

  • Condition/Disease

    Hair Loss

  • Test Drug

    ENERGI-F701

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

陳志強
Taipei Veterans General Hospital

Division of Dermatology

2010-08-01 - 2014-01-31

Phase III

LY2189265 compares with insulin Glargine and the combined use of insulin Lispro on the treatment to target of type 2 diabetes (AWARD-4: Evaluation of the weekly use of LY2189265 in patients with type 2 diabetes. 4 [Assessment of Weekly AdministRation of LY2189265 in Diabetes-4]

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2189265

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2009-07-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-04-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2011-07-01 - 2013-12-31

Phase III

A prospective, randomized, double-blind trial comparing the long-acting basal insulin analogue LY2963016 and Lantus® in adult patients with type 2 diabetes

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
8Sites

Terminated8Sites

1 37 38 39 40 41 43
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB